The authors would like to make the following corrections to this published paper [1]. In the original publication, there was a mistake in Figure 4 as published. Factual inaccuracies in Figure 4 were corrected. In fact, actual data do not support difference in efficacy between the respective vaccines as the primary endpoints from the clinical trials have been defined differently, and therefore no comparison between vaccines is appropriate, also taking into account the heterogeneous follow up during RSV seasons. The corrected Figure 4 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.
Figure 4.
Summary of the decline in vaccine efficacy (reported with their corresponding 95% Confidence Intervals [95%CI]) in the prevention of lower respiratory tract illnesses (LRTI) with 3 or more findings during first and second respiratory syncytial virus (RSV) season [28,87,210,213,221,241,243,258]. Preliminary data on Season 3 of RSVpreF3 have been retrieved from ACIP Meeting of 24 October 2024 [259]. The figure is not intended for vaccine comparison and in particular, the x axis does not represent a defined timeline, but seasonal efficacy only.
Reference
- Riccò, M.; Abu-Raya, B.; Icardi, G.; Spoulou, V.; Greenberg, D.; Pecurariu, O.F.; Hung, I.F.-N.; Osterhaus, A.; Sambri, V.; Esposito, S. Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options. Vaccines 2024, 12, 1317. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).